Friday, October 13, 2023 6:11:41 AM
"The Company believes that it has now completed all of the remaining prerequisites for such an application, including certain steps related to" "submission of the required formal notification to the MHRA of the upcoming MAA." "The Company anticipates submitting the MAA in approximately the next 30-45 days." https://www.gov.uk/guidance/guidance-on-150-day-assessment-for-national-applications-for-medicines. Within the guidance, they say that the company "should tell us the intended date of submission of the dossier". The press release states that NWBO completed the prerequisite of the "required formal notification to the MHRA of the upcoming MAA".
https://www.google.com/search?q=What+is+the+time+between+submission+and+acceptance+of+a+application+at+MHRA+%3F&rlz=1C1CHBD_nlNL901NL901&oq=What+is+the+time+between+submission+and+acceptance+of+a+application+at+MHRA+%3F&gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBCjM1NzQ2ajBqMTWoAgCwAgA&sourceid=chrome&ie=UTF-8
https://www.google.com/search?q=What+is+the+time+between+submission+and+acceptance+of+a+application+at+MHRA+%3F&rlz=1C1CHBD_nlNL901NL901&oq=What+is+the+time+between+submission+and+acceptance+of+a+application+at+MHRA+%3F&gs_lcrp=EgZjaHJvbWUyBggAEEUYOdIBCjM1NzQ2ajBqMTWoAgCwAgA&sourceid=chrome&ie=UTF-8
I am an Investment Advisor and run my own Investment Advisory Firm. Any comments are my own and are not to be used as investment advice. I own shares in NWBO
Recent NWBO News
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments • GlobeNewswire Inc. • 06/01/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
